Lisata Therapeutics, Inc. Files 2023 Annual Report on Form 10-K

Ticker: LSTA · Form: 10-K · Filed: Feb 29, 2024 · CIK: 320017

Sentiment: neutral

Topics: 10-K, Annual Report, Lisata Therapeutics, Pharmaceuticals, Financials

TL;DR

<b>Lisata Therapeutics, Inc. filed its 2023 10-K report detailing its operations and financial standing.</b>

AI Summary

LISATA THERAPEUTICS, INC. (LSTA) filed a Annual Report (10-K) with the SEC on February 29, 2024. Lisata Therapeutics, Inc. (formerly Caladrius Biosciences, Inc.) filed its annual report for the fiscal year ending December 31, 2023. The company's principal executive offices are located at 110 Allen Road, Second Floor, Basking Ridge, NJ 07920. The filing covers the period from January 1, 2023, to December 31, 2023. Lisata Therapeutics, Inc. is classified under the SIC code 2834 for Pharmaceutical Preparations. The company was formerly known as Caladrius Biosciences, Inc. and NeoStem, Inc. in prior name changes.

Why It Matters

For investors and stakeholders tracking LISATA THERAPEUTICS, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Lisata Therapeutics' financial performance, operational activities, and strategic direction for the fiscal year 2023. Investors and stakeholders can use this report to assess the company's historical performance, understand its current business model, and evaluate potential future risks and opportunities.

Risk Assessment

Risk Level: medium — LISATA THERAPEUTICS, INC. shows moderate risk based on this filing. The company's financial health and future prospects are subject to the inherent risks of the pharmaceutical industry, including regulatory hurdles, clinical trial outcomes, and market competition, as detailed in the 10-K filing.

Analyst Insight

Review the detailed financial statements and risk factors in the 10-K to understand Lisata Therapeutics' current financial position and strategic outlook.

Key Numbers

Key Players & Entities

FAQ

When did LISATA THERAPEUTICS, INC. file this 10-K?

LISATA THERAPEUTICS, INC. filed this Annual Report (10-K) with the SEC on February 29, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by LISATA THERAPEUTICS, INC. (LSTA).

Where can I read the original 10-K filing from LISATA THERAPEUTICS, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by LISATA THERAPEUTICS, INC..

What are the key takeaways from LISATA THERAPEUTICS, INC.'s 10-K?

LISATA THERAPEUTICS, INC. filed this 10-K on February 29, 2024. Key takeaways: Lisata Therapeutics, Inc. (formerly Caladrius Biosciences, Inc.) filed its annual report for the fiscal year ending December 31, 2023.. The company's principal executive offices are located at 110 Allen Road, Second Floor, Basking Ridge, NJ 07920.. The filing covers the period from January 1, 2023, to December 31, 2023..

Is LISATA THERAPEUTICS, INC. a risky investment based on this filing?

Based on this 10-K, LISATA THERAPEUTICS, INC. presents a moderate-risk profile. The company's financial health and future prospects are subject to the inherent risks of the pharmaceutical industry, including regulatory hurdles, clinical trial outcomes, and market competition, as detailed in the 10-K filing.

What should investors do after reading LISATA THERAPEUTICS, INC.'s 10-K?

Review the detailed financial statements and risk factors in the 10-K to understand Lisata Therapeutics' current financial position and strategic outlook. The overall sentiment from this filing is neutral.

How does LISATA THERAPEUTICS, INC. compare to its industry peers?

Lisata Therapeutics operates in the pharmaceutical preparations industry, focusing on the development of novel therapeutic agents.

Are there regulatory concerns for LISATA THERAPEUTICS, INC.?

The company is subject to the regulations of the U.S. Securities and Exchange Commission (SEC) for its public filings, including this 10-K report.

Industry Context

Lisata Therapeutics operates in the pharmaceutical preparations industry, focusing on the development of novel therapeutic agents.

Regulatory Implications

The company is subject to the regulations of the U.S. Securities and Exchange Commission (SEC) for its public filings, including this 10-K report.

What Investors Should Do

  1. Analyze the financial statements for revenue, expenses, and cash flow.
  2. Review the business description for details on product pipeline and development stage.
  3. Examine the risk factors section for potential challenges and uncertainties.

Key Dates

Year-Over-Year Comparison

This is the 2023 10-K filing, providing the latest annual financial and operational data for Lisata Therapeutics, Inc.

Filing Stats: 4,456 words · 18 min read · ~15 pages · Grade level 15.9 · Accepted 2024-02-29 16:12:50

Key Financial Figures

Filing Documents

RISK FACTORS 2 5

ITEM 1A. RISK FACTORS 2 5

UNRESOLVED STAFF COMMENTS 6 3

ITEM 1B. UNRESOLVED STAFF COMMENTS 6 3

CYBERSECURITY 6 3

ITEM 1C. CYBERSECURITY 6 3

PROPERTIES 6 5

ITEM 2. PROPERTIES 6 5

LEGAL PROCEEDINGS 6 5

ITEM 3. LEGAL PROCEEDINGS 6 5

MINE SAFETY DISCLOSURES 6 6

ITEM 4. MINE SAFETY DISCLOSURES 6 6 PART II

MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 6 7

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 6 7

[RESERVED] 6 7

ITEM 6. [RESERVED] 6 7

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 6 8

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 6 8

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 7 1

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 7 1

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 7 1

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 7 1

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 9 7

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 9 7

CONTROLS AND PROCEDURES 9 7

ITEM 9A. CONTROLS AND PROCEDURES 9 7

OTHER INFORMATION 98

ITEM 9B. OTHER INFORMATION 98

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 98

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 98 PART III

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 99

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 99

EXECUTIVE COMPENSATION

ITEM 11. EXECUTIVE COMPENSATION 1 01

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 102

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 102

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 1 02

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 1 02

PRINCIPAL ACCOUNTING FEES AND SERVICES 102

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES 102 PART IV

EXHIBITS, FINANCIAL STATEMENT SCHEDULES

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES 103

FORM 10-K SUMMARY 106

ITEM 16. FORM 10-K SUMMARY 106 2 Index CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This annual report (this "Annual Report") contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. When used in this Annual Report, statements that are not statements of current or historical fact may be deemed to be forward-looking statements, including, without limitation, all statements related to any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals; any other statements of expectations, plans, intentions or beliefs; and any statements of assumptions underlying any of the foregoing. Without limiting the foregoing, the words "plan," "project," "forecast," "outlook," "intend," "may," "will," "expect," "likely," "believe," "could," "anticipate," "estimate," "continue" or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity or our achievements or industry results, to be materially different from any future results, performance, levels of activity or our achievements or industry results expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially from anticipated results expressed or implied by forward-lo

BUSINESS

ITEM 1. BUSINESS. Overview Lisata Therapeutics, Inc. (together with its subsidiaries, "we," "us," "our," "Lisata" and the "Company") is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Our lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. LSTA1 also has the potential to modify the tumor microenvironment ("TME"), thereby making tumors more susceptible to immunotherapies and inhibiting the metastasis cascade (i.e., the spread of cancer to other parts of the body). We and our collaborators have amassed significant non-clinical data demonstrating enhanced delivery of a range of existing and emerging anti-cancer therapies, including chemotherapeutics, immunotherapies and RNA-based therapeutics. To date, LSTA1 has also demonstrated favorable safety, tolerability and activity in completed and ongoing clinical trials designed to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. Currently, LSTA1, is the subject of Phase 2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), cholangiocarcinoma, head and neck cancer, appendiceal cancer, colon cancer and glioblastoma multiforme in combination with a variety of anti-cancer regimens. Our legacy CD34+ cell therapy technology was the subject of several clinical trials targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dys

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing